Is the study population restricted to individuals with moderate cardiovascular risk (2-3 percent risk of events per year)?

The intent of this funding announcement is to extend evidence beyond that generated by randomized controlled trials published in the past five years; accordingly, proposed studies should include individuals at moderate cardiovascular risk and should be powered to assess outcomes in this patient population. The inclusion of individuals at a broader range of cardiovascular risk is permissible as long as studies are designed and powered to assess outcomes in a patient population at moderate cardiovascular risk.